HC Wainwright & Co. Assumes Cartesian Therapeutics at Buy, Announces Price Target of $2
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has initiated coverage on Cartesian Therapeutics (NASDAQ:RNAC) with a Buy rating and set a price target of $2.

March 04, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cartesian Therapeutics receives a Buy rating and a $2 price target from HC Wainwright & Co.
The initiation of coverage by a reputable analyst with a Buy rating and a specific price target usually leads to positive sentiment around the stock in the short term. Investors and traders often view such analyst ratings as credible signals of a stock's future performance, potentially driving up demand and the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100